	US 12,310,939 B2
	Method for treating rheumatoid arthritis
Michael E. Silver, Lake City, MI (US)
Assigned to The William Yarbrough Foundation, Peoria, IL (US)
Filed by THE WILLIAM M YARBROUGH FOUNDATION, Peoria, IL (US)
Filed on May 15, 2023, as Appl. No. 18/197,380.
Application 18/197,380 is a continuation of application No. 17/120,233, filed on Dec. 13, 2020, granted, now 11,648,230.
Application 17/120,233 is a continuation of application No. 16/814,473, filed on Mar. 10, 2020, granted, now 10,874,630, issued on Dec. 29, 2020.
Application 16/814,473 is a continuation of application No. 16/595,967, filed on Oct. 8, 2019, granted, now 10,583,108, issued on Mar. 10, 2020.
Application 16/595,967 is a continuation of application No. 16/025,579, filed on Jul. 2, 2018, granted, now 10,434,081, issued on Oct. 8, 2019.
Application 16/025,579 is a continuation in part of application No. 15/838,444, filed on Dec. 12, 2017, granted, now 10,111,852, issued on Oct. 30, 2018.
Application 15/838,444 is a continuation of application No. 15/423,869, filed on Feb. 3, 2017, granted, now 9,839,621, issued on Dec. 12, 2017.
Application 15/423,869 is a continuation in part of application No. 14/867,626, filed on Sep. 28, 2015, granted, now 9,642,827, issued on May 9, 2017.
Application 14/867,626 is a continuation of application No. 14/867,585, filed on Sep. 28, 2015, granted, now 9,636,320, issued on May 2, 2017.
Application 14/867,585 is a continuation of application No. 14/519,510, filed on Oct. 21, 2014, granted, now 9,504,667, issued on Nov. 29, 2016.
Application 14/519,510 is a continuation of application No. 13/952,236, filed on Jul. 26, 2013, granted, now 8,865,772, issued on Oct. 21, 2014.
Claims priority of provisional application 61/676,093, filed on Jul. 26, 2012.
Prior Publication US 2023/0338324 A1, Oct. 26, 2023
Int. Cl. A61K 31/26 (2006.01); A61K 9/00 (2006.01); A61K 31/16 (2006.01); A61K 31/195 (2006.01); A61K 31/198 (2006.01)

CPC A61K 31/26 (2013.01) [A61K 9/0014 (2013.01); A61K 31/16 (2013.01); A61K 31/195 (2013.01); A61K 31/198 (2013.01)]

20 Claims

1. A method of treating rheumatoid arthritis comprising the step of:

administering a product that is a leave-on product or a leave-in product to a patient having rheumatoid arthritis wherein the product comprises an isothiocyanate functional surfactant and an additional surfactant, wherein the additional surfactant is chosen from the group consisting of a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof;

wherein the anionic surfactant is chosen from the group comprising taurates; isethionates; alkyl and alkyl ether sulfates; succinamates; alkyl sulfonates, alkylaryl sulfonates; olefin sulfonates; alkoxy alkane sulfonates; sodium and potassium salts of fatty acids derived from natural plant or animal sources or synthetically prepared; sodium, potassium, ammonium, and alkylated ammonium salts of alkylated and acylated amino acids and peptides; alkylated sulfoacetates; alkylated sulfosuccinates; acylglyceride sulfonates, alkoxyether sulfonates; phosphoric acid esters; phospholipids; ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium stearoyl isethionate, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, sodium lauryl sarcosinate, disodium laureth sulfosuccinate, sodium lauryl sulfoacetate, sodium cocoyl glutamate, TEA-cocoyl glutamate, TEA cocoyl alaninate, sodium cocoyl taurate, potassium cetyl phosphate; and

wherein the isothiocyanate functional surfactant is in a protonated form and wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: